Feedback / Questions
elraglusib (9-ING-41) - Actuate Therap
https://www.globenewswire.com/news-release/2025/06/20/3102706/0/en/Actuate-Therapeutics-Reports-Positive-Biomarker-and-Machine-Learning-Data-from-Phase-2-Elraglusib-Trial-in-First-Line-Treatment-of-Metastatic-Pancreatic-Cancer-at-ASCO.html
Jun 20, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next